Extending the benefit ef lipid-reguulating therapy to primary prevention Academic Article Article uri icon


MeSH Major

  • Lipoproteins, HDL


  • In recent years, a number of published secondary prevention trials have further strengthened the rationale for aggressive lipid-regulating therapy in patients with established coronary artery disease. However, the role of lipid-regulating therapy in primary prevention is less well characterized. Several large primary prevention trials, using a variety of interventions, are ongoing in different populations. These include the Air Force Coronary/Texas Atherosclerosis Prevention Study, the West of Scotland Coronary Prevention Study, the Women's Health Initiative, and the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. These investigations will extend the results of earlier primary prevention trials and further characterize the rationale for intervention.

publication date

  • September 28, 1995



  • Academic Article


Digital Object Identifier (DOI)

  • 10.1016/S0002-9149(99)80481-0

PubMed ID

  • 7572680

Additional Document Info

start page

  • 118C

end page

  • 121C


  • 76


  • 9 SUPPL. 1